1,384 results match your criteria Calciphylaxis


Non-Uremic Calciphylaxis: A Rare Diagnosis with Limited Therapeutic Strategies.

Eur J Case Rep Intern Med 2018 27;5(12):000986. Epub 2018 Dec 27.

Unidade Funcional de Medicina 2.1, Hospital de Santo António dos Capuchos, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.

Calciphylaxis is a rare condition characterized by the emergence of non-healing skin ulcers secondary to arterial calcification and thrombosis, typically diagnosed in patients with end-stage kidney disease (ESKD). When it develops in patients without ESKD, it is called non-uremic calciphylaxis (NUC). The latter is an even rarer diagnosis with an uncertain pathophysiology and a high mortality rate (52%), mainly due to sepsis (50%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2018_000986DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346971PMC
December 2018

Bilateral Mastodynia: An Unusual Presentation of Calciphylaxis.

Acta Med Port 2019 Feb 1;32(1):86. Epub 2019 Feb 1.

Senology Unit. Department of Gynecology and Obstetrics. Setúbal Medical Centre. Setúbal. Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20344/amp.10495DOI Listing
February 2019
1 Read

A Catastrophic Case of Idiopathic Cholesterol Crystal Embolism with Multiple Lethal Complications: A Labyrinth Underneath the Diagnosis of Skin Ulcers in Chronic Kidney Disease Patients.

Intern Med 2019 Feb 1. Epub 2019 Feb 1.

Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Japan.

A 66-year-old man was admitted to our hospital because of multiple refractory skin ulcers. Based on his severe systemic arterial calcification and severe calcium-phosphate imbalance due to severe kidney dysfunction, we initially considered calciphylaxis. However, a skin biopsy provided a diagnosis of cholesterol crystal embolization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.2378-18DOI Listing
February 2019
1 Read

Non-uremic calciphylaxis associated with alcoholic hepatitis: A case report.

World J Hepatol 2019 Jan;11(1):127-132

Department of Dermatology, Cleveland Clinic, Cleveland 44195, OH, United States.

Background: Calciphylaxis is a form of vascular calcification more commonly associated with renal disease. While the exact mechanism of calciphylaxis is poorly understood, most cases are due to end stage kidney disease. However, it can also be found in patients without kidney disease and in such cases is termed non-uremic calciphylaxis for which have multiple proposed etiologies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4254/wjh.v11.i1.127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354123PMC
January 2019
1 Read

Sodium thiosulfate and pamidronate for treatment of calciphylaxis: case report.

Colomb Med (Cali) 2018 Dec 30;49(4):288-291. Epub 2018 Dec 30.

Complejo Asistencial Universitario de León, Servicio de Nefrología, León, España.

Introduction: Calciphylaxis is an infrequent disease that almost exclusively affects patients with chronic kidney disease, although cases have been observed in patients without renal function impairment. The diagnosis is mainly made by clinical manifestations and subsequently confirmed by radiological and histological study. The optimal treatment is not known, although there is a consensus that a multifactorial approach is required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.25100/cm.v49i3.4134DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342083PMC
December 2018
6 Reads

The use of cinacalcet for the treatment of calciphylaxis in patients with chronic kidney disease: A comprehensive review.

Australas J Dermatol 2019 Jan 21. Epub 2019 Jan 21.

Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Calciphylaxis is a rare but life-threatening condition, most commonly affecting patients with stage 4 or 5 chronic kidney disease. No universally accepted therapy exists so far. In an attempt to avoid surgical intervention with parathyroidectomy, which is of questionable efficacy and carries several risks, a number of noninvasive treatments have been trialled with variable success. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.12992DOI Listing
January 2019
2 Reads

Calciphylaxis and nephrogenic fibrosing dermopathy with pseudoxanthoma elasticum-like changes: Successful treatment with sodium thiosulfate.

J Dermatol 2019 Jan 21. Epub 2019 Jan 21.

Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.14780DOI Listing
January 2019
4 Reads

Sodium thiosulfate in calciphylaxis: Make a long story short.

JAAD Case Rep 2019 Jan 4;5(1):19-20. Epub 2018 Dec 4.

Nephrology Department, General Hospital of Livadeia, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.09.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323651PMC
January 2019
1 Read

Update on calciphylaxis etiopathogenesis, diagnosis, and management.

Cutis 2018 Dec;102(6):395-400

Departments of Dermatology and Medicine, University of Pennsylvania, Philadelphia, USA.

Calciphylaxis is a rare painful skin condition classically seen in patients with end-stage renal disease (ESRD), particularly those on chronic dialysis; however, it also has been increasingly reported in patients with normal renal function. Calciphylaxis is associated with high mortality rates, and excruciating pain and nonhealing ulcers often lead to recurrent hospitalizations and infectious complications. It is critical for dermatologists to recognize the clinical features of calciphylaxis to ensure accurate and timely diagnosis and proper management. Read More

View Article

Download full-text PDF

Source
December 2018
2 Reads

[Early diagnosis, prevention and treatment for calcific uremic arteriolopathy].

Zhong Nan Da Xue Xue Bao Yi Xue Ban 2018 Nov;43(11):1251-1256

Department of Nephrology, Third Xiangya Hospital, Central South University, Changsha 410013, China.

Calcific uremic arteriopathy (CUA), termed calciphylaxis, is a rare but highly fatal clinical syndrome. There is no clearly laboratory diagnostic criteria for CUA. The medium and small arterial calcification and microthrombosis discovered by skin biopsy, radiologic imaging,bone scan and the evidence of activation of the bone morphogenetic protein signal (BMPs) transduction pathway are useful for early diagnosis of this disease. Read More

View Article

Download full-text PDF

Source
http://www.csumed.org/xbwk/CN/10.11817/j.issn.1672-7347.2018
Publisher Site
http://dx.doi.org/10.11817/j.issn.1672-7347.2018.11.014DOI Listing
November 2018
5 Reads

A Phase 1b Randomized, Placebo-Controlled Clinical Trial with SNF472 in Hemodialysis Patients.

Br J Clin Pharmacol 2019 Jan 10. Epub 2019 Jan 10.

Laboratoris Sanifit, Palma, Spain.

Aims: SNF472 is a calcification inhibitor that is being studied as a novel treatment for calciphylaxis and cardiovascular calcification (CVC). A first study showed acceptable safety and tolerability in a single ascending dose administration in healthy volunteers and a single dose administration in haemodialysis (HD) patients. This study aimed to assess the safety, tolerability, and pharmacokinetics (PK)/pharmacodynamics (PD) relationship of intravenous (iv) SNF472 in HD patients in a multiple ascending dose administration trial with 5 doses tested for one week (three administrations) and one dose tested for four weeks (12 administrations). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.13863DOI Listing
January 2019
1 Read

The Effectiveness of Topical Cerium Nitrate-Silver Sulfadiazine Application on Overall Outcome in Patients with Calciphylaxis.

Dermatology 2019 Jan 3:1-10. Epub 2019 Jan 3.

Department of Nephrology and Organ Transplantation, Center for Rare Renal Disease, University Hospital of Toulouse, Toulouse,

Background: Calciphylaxis (CPX) is a rare and life-threatening disease characterized by vascular calcification and development of painful and necrotizing skin lesions with a challenging management. Mechanisms of CPX are complex and include an imbalance between vascular calcification promoters and inhibitors, and frequently vitamin K deficiency.

Objectives: To describe the various presentations and identify predictive factors of death in patients with CPX. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493975DOI Listing
January 2019
1 Read

Demographics, Comorbid Conditions, and Outcomes of Patients With Nonuremic Calciphylaxis.

JAMA Dermatol 2019 Jan 2. Epub 2019 Jan 2.

Division of Dermatology, Department of Medicine, University of Washington, Seattle.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2018.4937DOI Listing
January 2019
1 Read

Removing the problem: parathyroidectomy for calciphylaxis.

BMJ Case Rep 2018 Dec 22;11(1). Epub 2018 Dec 22.

Department of Internal Medicine, Michigan State University College of Human Medicine, East Lansing, Michigan, USA.

Calcific uremic arteriolopathy (CUA), widely known as calciphylaxis, is a rare and lethal disease that usually affects patients with end-stage renal disease. It is characterised by widespread vascular calcification leading to tissue ischaemia and necrosis and formation of characteristic skin lesions with black eschar. Treatment options include sodium thiosulfate, cinacalcet, phosphate binders and in resistant cases, parathyroidectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-226696DOI Listing
December 2018
5 Reads

Medication-Related Osteonecrosis of the Jaw in a Patient with Nonuremic Calciphylaxis.

Skinmed 2018 21;16(6):424-426. Epub 2018 Dec 21.

Department of Dermatology and Venereology, Centro Hospitalar São João, EPE, Porto, Portugal.

A 62-year-old man was referred to the emergency department of our hospital with pain and swelling in the left mandibular region that had evolved over the previous 2 months (Figure 1). His medical history included nonuremic calciphylaxis and systemic sclerosis (Figure 2). Since the diagnosis of the nonuremic calciphylaxis 5 years before, the patient had been treated with intravenous (IV) sodium pamidronate 60 mg per week for 11 months, without improvement, followed by IV sodium thiosulfate 25 mg twice a week for 18 month. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

Calciphylaxis-as a drug induced adverse event.

Expert Opin Drug Saf 2019 Jan 24;18(1):29-35. Epub 2018 Dec 24.

d Division of Nephrology, Department of Medicine , Massachusetts General Hospital , Boston , MA , USA.

Introduction: Calciphylaxis is a rare but devastating disease with a mortality rate up to 50% in 1 year. It is characterized by profoundly painful ischemic skin lesions and vascular calcification that affects predominantly patients with end stage renal disease. The use of certain medications is an important modifiable risk factor in calciphylaxis and discontinuation of these is a mainstay of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2019.1559813DOI Listing
January 2019
1 Read

Chronic Kidney Disease and Calciphylaxis: A Literature Review.

Cureus 2018 Sep 19;10(9):e3334. Epub 2018 Sep 19.

Internal Medicine, King Edward Medical University, Mayo Hospital, Lahore, PAK.

Calcific uremic arteriolopathy (CUA), also known as calciphylaxis, is a rare complication of chronic kidney disease (CKD). Its incidence is increasing due to a better understanding and diagnosis by physicians. Calciphylaxis is a fatal complication of many metabolic disorders. Read More

View Article

Download full-text PDF

Source
https://www.cureus.com/articles/14608-chronic-kidney-disease
Publisher Site
http://dx.doi.org/10.7759/cureus.3334DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248774PMC
September 2018
8 Reads

Hans Selye and his studies on the role of mast cells in calciphylaxis and calcergy.

Authors:
Domenico Ribatti

Inflamm Res 2019 Feb 19;68(2):177-180. Epub 2018 Nov 19.

Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Policlinico -Piazza G. Cesare, 11, 70124, Bari, Italy.

Hans Selye was an endocrinologist, a pioneer of research on biological stress in human individuals and groups. His most important scientific contributions include in 1936 the evidence that the pituitary-adrenal-thymus axis was activated by various nocuous stimuli, which led to the involution of the thymus and of the lymphoid organs; in 1946, the theory of general adaptation syndrome (GAS), pointing out that this is a general reaction that leads to resistance of the organism to various insults. This review article is focused on the general interest of Selye on the important role played by mast cells in different pathological conditions and in particular in calciphylaxis and calcergy, summarized in a classic book, which is a lasting contribution on the subject. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00011-018-1199-7DOI Listing
February 2019
1 Read

A Rare Case of Multiorgan Calciphylaxis in a Patient with Stage 5 Chronic Kidney Disease.

Case Rep Urol 2018 18;2018:9603680. Epub 2018 Oct 18.

Department of Urology, Aladan Hospital, Kuwait.

Calciphylaxis or calcific uremic arteriolopathy (CUA) is a potentially life-threatening vasculopathy involving the skin and subcutaneous tissues. It is usually associated with chronic kidney disease (CKD) and rarely with acute renal failure or predialysis patients. The clinical diagnosis of calcific uremic arteriolopathy relies on high index of suspicion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/9603680DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211149PMC
October 2018
2 Reads

Calciphylaxis in patients with chronic kidney disease: A disease which is still bewildering and potentially fatal.

Nefrologia 2018 Nov - Dec;38(6):579-586. Epub 2018 Nov 8.

Servicio de Nefrología y Trasplante Renal, Hospital Clínic, Barcelona, España. Electronic address:

Calciphylaxis, also known as calcific uraemic arteriolopathy, is a rare syndrome that typically causes skin necrosis and usually affects dialysis patients. Its pathogenesis is multifactorial and is the consequence of many factors causing ectopic calcifications in patients with chronic kidney disease, such as calcium-phosphate metabolism disorders, hyper- or hypo-parathyroidism, diabetes, obesity, systemic inflammation and the use of vitamin K antagonists, among others. From a clinical point of view, calciphylaxis may progress from painful purpura to extensive areas of skin necrosis that can potentially lead to superinfection and the death of the patient due to sepsis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nefro.2018.05.007DOI Listing
November 2018
2 Reads

[Calcific uremic arteriolopathy in hemodialysis patient, review of literature through five cases reports].

Nephrol Ther 2018 Nov 29;14(6):439-445. Epub 2018 Jun 29.

Service de néphrologie-hémodialyse et transplantation rénale, université Cadi Ayyad, CHU Mohammed VI, BP 2360 Principal, avenue Ibn Sina, Marrakech, Maroc.

Calcific uremic arteriolopathy, also called calciphylaxis, is a rare and severe disorder that presents with skin ischemia and necrosis, sometimes it presents with systemic necrosis, the process is secondary to the obliteration of the arterioles first by sub-intimal calcium deposits and then by thrombosis. These lesions can often lead to death due to infectious complications and comorbidities such as diabetes, obesity, arteritis, diffuse vascular calcifications, heart disease and undernutrition. The diagnosis is suggested by the characteristic ischemic skin lesions and their distribution, often bilateral and painful, associeted with calcific uremic arteriolopathy risk factors (phosphocalcic abnormalities, anti-vitamin K). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S17697255183013
Publisher Site
http://dx.doi.org/10.1016/j.nephro.2018.04.004DOI Listing
November 2018
12 Reads

Palliative Care Use and Patterns of End-of-Life Care in Hospitalized Patients With Calciphylaxis.

J Pain Symptom Manage 2019 Feb 3;57(2):e1-e3. Epub 2018 Nov 3.

Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Medicine, Palliative and Advanced Illness Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpainsymman.2018.10.514DOI Listing
February 2019
3 Reads

Management of Penile Calciphylaxis: A Case Study.

J Wound Ostomy Continence Nurs 2018 Nov/Dec;45(6):536-539

Jacqueline M. Zillioux, MD, Department of Urology, University of Virginia, Charlottesville. Alexander Geisenhoff, BS, School of Medicine, Rush University, Chicago, Illinois. Mikel Gray, PhD, Department of Urology, University of Virginia, Charlottesville.

Background: Calciphylaxis, also called calcific uremic arteriolopathy, is a highly morbid syndrome characterized by calcium deposition and occlusion of small arterial vessels of the dermis and subdermal adipose tissue, leading to necrosis and gangrene. Penile involvement is rare and its management presents considerable challenges.

Case: We review the case of a 47-year-old man with end-stage renal disease managed with hemodialysis, diabetes mellitus, and urinary incontinence who presented with a painful necrotic lesion on his glans penis, and the second and third toes of his right foot. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WON.0000000000000483DOI Listing
November 2018
9 Reads

Non-uraemic calciphylaxis successfully treated with pamidronate infusion.

Int Wound J 2019 Feb 4;16(1):250-255. Epub 2018 Nov 4.

Department of Orthopaedics, Geisinger Medical Center, Danville, Pennsylvania.

Calciphylaxis is a rare and potentially fatal disease that affects the subcutaneous layer of the skin. It is a calcific vasculopathy induced by a systemic process that causes occlusion of small blood vessels. The mortality rate for individuals diagnosed with calciphylaxis is estimated between 52% and 81% with sepsis being the leading cause of death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iwj.13019DOI Listing
February 2019
1 Read

[Hyperthyroidism-induced calciphylaxis: A case report].

Nephrol Ther 2018 Dec 29;14(7):548-553. Epub 2018 Oct 29.

Service de néphrologie, groupe hospitalier La Pitié-Salpêtrière, 75013 Paris, France. Electronic address:

Background: Calciphylaxis or calcific uremic arteriolopathy (CUA) is a cutaneous disease with ulcerations secondary to calcification of cutaneous and subcutaneous small arteries and arterioles. It is a rare but severe disease with significant morbidity and mortality affecting 1 to 4% of dialysis patients. The circumstances of occurrence are multiple. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nephro.2018.08.001DOI Listing
December 2018
16 Reads

Non-uraemic calciphylaxis (NUC) postliver transplantation.

BMJ Case Rep 2018 Oct 24;2018. Epub 2018 Oct 24.

Medicine; Endocrinology, Diabetes and Nutrition, University of Maryland Medical Center, Baltimore, Maryland, USA.

Calciphylaxis is a rare and life-threatening disease characterized by cutaneous arteriolar stenosis and vascular thrombosis leading to skin ischaemia and necrosis. While calciphylaxis occurs mostly in patients with end-stage renal disease, the disorder has been described in patients with normal renal function, namely non-uraemic calciphylaxis (NUC). A 41-year-old African-American woman presented with a painful ulcerative rash on her thighs and right buttock 2 months after undergoing an orthotopic liver transplantation. Read More

View Article

Download full-text PDF

Source
http://casereports.bmj.com/lookup/doi/10.1136/bcr-2018-22653
Publisher Site
http://dx.doi.org/10.1136/bcr-2018-226537DOI Listing
October 2018
12 Reads

Long-Term Anticoagulation for Patients Receiving Dialysis.

Circulation 2018 Oct;138(15):1530-1533

Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston (S.U.N., R.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037091DOI Listing
October 2018

Management of calciphylaxis in a burn center: A case series and review of the literature.

Burns 2019 Feb 12;45(1):241-246. Epub 2018 Oct 12.

Burn Center, US Army Institute of Surgical Research, Fort Sam Houston, TX, United States; Uniformed Services University of the Health Sciences, Bethesda, MD, United States. Electronic address:

Calciphylaxis is a rare, necrotizing skin disorder usually associated with kidney disease, but also caused by many other systemic illnesses. This disease is associated with mortality rates as high as 80% at 1year. We present the demographic and clinical data of nine patients with calciphylaxis treated at our burn center over a 10year period. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03054179183031
Publisher Site
http://dx.doi.org/10.1016/j.burns.2018.09.008DOI Listing
February 2019
24 Reads

Calciphylaxis in a kidney transplant patient.

Rev Clin Esp 2018 Oct 9. Epub 2018 Oct 9.

Servicio de Dermatología, Complejo Hospitalario de Toledo, Toledo, España.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00142565183023
Publisher Site
http://dx.doi.org/10.1016/j.rce.2018.08.004DOI Listing
October 2018
1 Read

Review: update on the management of calciphylaxis.

QJM 2019 Jan;112(1):29-34

Division of Nephrology, Department of Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.

Calciphylaxis is a disease of significant morbidity and mortality, predominantly affecting dialysis patients. The term 'calciphylaxis' was coined by Seyle et al. in 1961 to describe calcium deposition in the skin and subcutaneous soft tissue of uremic rats in response to 'triggers' (e. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/qjmed/advance-article/doi/10.1093/q
Publisher Site
http://dx.doi.org/10.1093/qjmed/hcy234DOI Listing
January 2019
7 Reads

Multi-intervention management of calcific uremic arteriolopathy in 24 patients.

Clin Kidney J 2018 Oct 9;11(5):704-709. Epub 2018 Mar 9.

Department of Medicine, Division of Nephrology, University of British Columbia, Vancouver, BC, Canada.

Background: Calcific uremic arteriolopathy (CUA), also known as calciphylaxis, is a rare but life-threatening condition predominately occurring in patients with end-stage renal disease on dialysis. In the absence of randomized clinical trials to guide management, clinicians must rely on observational data. We have previously reported the outcomes of our multi-intervention management in seven patients and now present a larger series of patients with extended follow-up. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ckj/article/11/5/704/4925437
Publisher Site
http://dx.doi.org/10.1093/ckj/sfy007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165754PMC
October 2018
5 Reads

Factors associated with false-negative pathologic diagnosis of calciphylaxis.

J Cutan Pathol 2019 Jan 4;46(1):16-25. Epub 2018 Nov 4.

Massachusetts General Hospital, Dermatopathology Unit, Department of Pathology, Boston, Massachusetts.

Background: Calciphylaxis is a rare, painful, and debilitating disorder of vascular calcification and skin necrosis that typically affects patients with advanced kidney disease. During our routine pathology practice, we noted several missed diagnoses on calciphylaxis consultation cases originating from outside institutions and sought to explore factors associated with false-negative pathologic diagnosis of calciphylaxis.

Methods: The pathology database of a large tertiary academic medical center was retrospectively searched for "calciphylaxis" in inside reports on outside surgical consultation cases between 2007 and 2017. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cup.13364
Publisher Site
http://dx.doi.org/10.1111/cup.13364DOI Listing
January 2019
3 Reads

First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification.

Br J Clin Pharmacol 2018 Dec 3;84(12):2867-2876. Epub 2018 Oct 3.

Laboratoris Sanifit, Palma, Spain.

Aims: SNF472 is a calcification inhibitor being developed for the treatment of cardiovascular calcification in haemodialysis (HD) and in calciphylaxis patients. This study investigated the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) SNF472 in healthy volunteers (HV) and HD patients.

Methods: This is a first-time-in-human, double-blind, randomized, placebo-controlled Phase I study to assess the safety, tolerability and PK of SNF472 after ascending single IV doses in HV and a single IV dose in HD patients. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bcp.13752
Publisher Site
http://dx.doi.org/10.1111/bcp.13752DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255995PMC
December 2018
7 Reads

CRYSTALLINE RETINOPATHY AND RETINAL VASCULOPATHY IN CALCIFIC UREMIC ARTERIOLOPATHY (CALCIPHYLAXIS).

Retin Cases Brief Rep 2018 Fall;12(4):331-335

Vitreous Retina Macula Consultants of New York, New York.

Purpose: To report the posterior segment and retinal vascular manifestations of calcific uremic arteriolopathy (calciphylaxis). Clinical findings are correlated with multimodal imaging results.

Methods: Observational case report. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/ICB.0000000000000494DOI Listing
September 2018
8 Reads

Nonuremic Calciphylaxis.

J Clin Rheumatol 2018 Sep 27. Epub 2018 Sep 27.

From the American University of the Caribbean, Coral Gables, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000899DOI Listing
September 2018
2 Reads

Calciphylaxis: Case Presentation and Review of the Literature.

J Wound Ostomy Continence Nurs 2018 Nov/Dec;45(6):532-535

Richard Masoetsa, MPod, Podiatry, Dasman Diabetes Institution, Dasman, Kuwait. Ala A'Groof, MD, FRCSC, Vascular Surgery, Dasman Diabetes Institution, Dasman, Kuwait. Madan Kapoor, DM (Nephro); FRCP (EDIN), Nephrology, Dasman Diabetes Institution, Dasman, Kuwait. Grace Messenger, MRes, Podiatry, Dasman Diabetes Institution, Dasman, Kuwait. Imtiaz Hussain, BSc Honours, Podiatry, Dasman Diabetes Institution, Dasman, Kuwait.

Background: Calciphylaxis is a potentially life-threatening condition involving painful necrotic skin ulcerations, especially of the lower extremities. It is generally associated with chronic kidney failure but may be seen in nonuremic cases.

Case Report: We report a case of calciphylaxis in a 60-year-old man with diabetes on dialysis for end-stage renal disease and known to have other typical combination of risk factors associated with calciphylaxis syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WON.0000000000000473DOI Listing
September 2018
16 Reads

Nonuremic Calciphylaxis: Four Cases Associated with Autoimmune Diseases.

Skinmed 2018 1;16(4):235-237. Epub 2018 Jul 1.

From the Department of Dermatology and Venereology, Centro Hospitalar São João, EPE, Porto, Portugal.

Calciphylaxis is a rare and severe syndrome of vascular calcification with unclear pathogenesis. This disease mainly affects patients with end-stage renal disease; however, it also has been described in nonuremic patients. We report four cases of nonuremic calciphylaxis (NUC) with ulcerated lesions associated with autoimmune disease. Read More

View Article

Download full-text PDF

Source
July 2018
15 Reads

Dysphagia in a Patient With End-Stage Renal Disease.

Gastroenterology 2018 12 8;155(6):e11-e12. Epub 2018 Sep 8.

Department of Internal Medicine, Section of Digestive Diseases and Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2018.07.053DOI Listing
December 2018

Calciphylaxis in Patients With Preserved Renal Function: Worrisome Wounds.

Mayo Clin Proc 2018 Sep;93(9):1164-1166

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2018.07.009DOI Listing
September 2018
1 Read

Arteriolar vs. valvular thrombosis: Pick your evil!

Thromb J 2018 29;16:23. Epub 2018 Aug 29.

St John Providence-Providence Park Hospitals, 19001 W. 9 Mile Rd, Southfield, MI 48075 USA.

Background: Anticoagulation therapy for mechanical prosthetic valves is limited to vitamin K antagonists, unfractionated heparin and low-molecular-weight-heparin. Other forms of anticoagulation are either contraindicated or have not been well studied. Hence, anticoagulation for preexisting mechanical valves is controversial if vitamin K antagonists are contraindicated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12959-018-0175-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114737PMC
August 2018
10 Reads

The Successful Use of Apixaban in Dialysis Patients with Calciphylaxis Who Require Anticoagulation: A Retrospective Analysis.

Am J Nephrol 2018 3;48(3):168-171. Epub 2018 Sep 3.

Department of Dermatology, Boston, Massachusetts, USA.

Calciphylaxis is a disease of dermal arteriolar calcification that results in necrosis. It commonly occurs in individuals with end-stage renal disease (ESRD) on hemodialysis and is associated with a high morbidity and mortality. Warfarin use is an identified risk factor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000491881DOI Listing
September 2018
6 Reads

A New Treatment for Calciphylaxis in Hemodialysis Patients?

Am J Nephrol 2018 3;48(3):165-167. Epub 2018 Sep 3.

CNR-IFC, Clinical Epidemiology and Pathophysiology of Hypertension and Renal Diseases, Reggio Calabria, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000491882DOI Listing
September 2018
3 Reads

Diagnostic challenges in a patient with calciphylaxia - a case report.

Rom J Morphol Embryol 2018 ;59(2):591-594

Department of Internal Medicine and Rheumatology, "Dr. Ion Cantacuzino" Hospital, Bucharest, Romania;

Calciphylaxis is a condition with unclear etiopathogeny with vascular calcifications and thrombotic occlusion that lead to necrotic lesions. It is usually described in patients with end-stage renal disease (ESRD), but also in other conditions. The mortality rate is high, due to sepsis and internal organ failure. Read More

View Article

Download full-text PDF

Source
December 2018
16 Reads

Pathology of Peripheral Artery Disease in Patients With Critical Limb Ischemia.

J Am Coll Cardiol 2018 Oct 27;72(18):2152-2163. Epub 2018 Aug 27.

Mount Sinai Heart and Icahn School of Medicine at Mount Sinai, New York, New York.

Background: Critical limb ischemia (CLI) is the most serious complication of peripheral artery disease (PAD).

Objectives: The purpose of this study was to characterize pathology of PAD in below- and above-knee amputation specimens in patients presenting with CLI.

Methods: Peripheral arteries from 95 patients (121 amputation specimens) were examined; 75 patients had presented with CLI, and the remaining 20 had amputations performed for other reasons. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07351097183575
Publisher Site
http://dx.doi.org/10.1016/j.jacc.2018.08.002DOI Listing
October 2018
37 Reads

Penile lesion in a dialysis patient: Time to get an X-ray.

Clin Case Rep 2018 Aug 25;6(8):1641-1642. Epub 2018 Jun 25.

Division of Nephrology, Hypertension and Renal Transplantation University of Florida Gainesville FL USA.

Calciphylaxis or calcific uremic arteriolopathy is a rare and serious disorder typically seen in patients with end-stage renal disease that manifests as skin ischemia and necrosis and histologically characterized by calcification of dermal arterioles. Penis is a rare site of involvement and biopsy is not typically recommended, making the diagnosis clinico-radiologic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.1669DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099032PMC
August 2018
2 Reads

Protracted Hypocalcemia following 3.5 Parathyroidectomy in a Kidney Pancreas Recipient with a History of Robotic-Assisted Roux-en-Y Gastric Bypass.

Case Rep Transplant 2018 24;2018:2182083. Epub 2018 Jul 24.

Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.

Background: Hypocalcemia is a frequent complication of parathyroidectomy for secondary/tertiary hyperparathyroidism. In patients with a history of prior Roux-en-Y gastric bypass (RYGBP), changes in nutritional absorption make management of hypocalcemia after parathyroidectomy difficult.

Case Report: A 41-old-year morbidly obese female with c-peptide negative diabetes mellitus and renal failure had RYGBP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/2182083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081600PMC
July 2018
5 Reads

Calciphylaxis in a dialysis patient successfully treated with high-dose vitamin K supplementation.

Clin Kidney J 2018 Aug 10;11(4):528-529. Epub 2017 Nov 10.

Canberra Hospital Renal Unit, Garran, ACT, Australia.

Calciphylaxis has high mortality. Vitamin K deficiency is common in haemodialysis patients and may be a trigger for calciphylaxis due to its role in activating matrix Gla protein (a tissue inhibitor of calcification). We report the case of a 43-year-old female haemodialysis patient who developed calciphylaxis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ckj/sfx126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070075PMC
August 2018
3 Reads

[63-Year-Old Patient Suffering from Painful Skin Disease].

Dtsch Med Wochenschr 2018 Aug 7;143(16):1155-1156. Epub 2018 Aug 7.

Klinik für Innere Medizin und Nephrologie, Universitätsklinikum Marburg.

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/a-0652-1921
Publisher Site
http://dx.doi.org/10.1055/a-0652-1921DOI Listing
August 2018
5 Reads

Calciphylaxis in Patients With Normal Renal Function: A Case Series and Systematic Review.

Mayo Clin Proc 2018 Sep 27;93(9):1202-1212. Epub 2018 Jul 27.

Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA. Electronic address:

Objective: To define concomitant risk factors, treatment, and outcomes for patients with nonnephrogenic calciphylaxis (NNC).

Patients And Methods: A retrospective review of Massachusetts General Hospital (MGH) medical records (January 1, 2014, through February 29, 2016) and a systematic literature review of PubMed, Google Scholar, EMBASE, MEDLINE, and CENTRAL (August 1, 1970, through July 31, 2016) were performed. Demographic characteristics and concomitant features were summarized and compared between patients with different lesion characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2018.06.001DOI Listing
September 2018
7 Reads